Literature DB >> 3606749

Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.

M Takahashi, S Iwasaki, H Kobayashi, S Okuda, T Murai, Y Sato, T Haraguchi-Hiraoka, H Nagano.   

Abstract

The mode of action of rhizoxin (1a), a new antitumor macrolide, was investigated. Rhizoxin inhibited fusion of the male and the female pronuclei in fertilized sea urchin eggs and inhibited cilia formation in the deciliated sea urchin embryos. In vitro, polymerization of tubulin isolated from porcine brains was completely inhibited at a 1 X 10(-5) M concentration of rhizoxin, and tubulin which had been polymerized by incubation at 37 degrees C for 30 minutes was depolymerized by addition of 1 X 10(-5) M of the drug. Activity of rhizoxin against tubulin polymerization was compared with those of other anti-tubulin drugs such as colchicine, vinblastine and ansamitocin P-3. The homologues of rhizoxin, 1b-3b, also inhibited polymerization of the purified microtuble protein at almost the same extent as rhizoxin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606749     DOI: 10.7164/antibiotics.40.66

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  11 in total

1.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Molecular basis for determining the sensitivity of eucaryotes to the antimitotic drug rhizoxin.

Authors:  M Takahashi; S Matsumoto; S Iwasaki; I Yahara
Journal:  Mol Gen Genet       Date:  1990-07

3.  Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

Authors:  T Tokui; N Maeda; C Kuroiwa; K Sasagawa; T Inoue; K Kawai; T Ikeda; T Komai
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

4.  Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Mingfu Liu; Georgios Chamilos; Dimitrios Kontoyiannis; Richard Mink; Kyung J Kwon-Chung; Yue Fu; Christopher D Skory; John E Edwards; Brad Spellberg
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

5.  Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway.

Authors:  T Tokui; T Takatori; N Shinozaki; M Ishigami; A Shiraishi; T Ikeda; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.

Authors:  T Takatori; T Koizumi; T Tokui; Y Mitsuhashi; A Shiraishi; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans.

Authors:  M Takahashi; H Kobayashi; S Iwasaki
Journal:  Mol Gen Genet       Date:  1989-12

8.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly.

Authors:  T Usui; M Kondoh; C B Cui; T Mayumi; H Osada
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

Review 9.  Evolution of small prokaryotic genomes.

Authors:  David J Martínez-Cano; Mariana Reyes-Prieto; Esperanza Martínez-Romero; Laila P Partida-Martínez; Amparo Latorre; Andrés Moya; Luis Delaye
Journal:  Front Microbiol       Date:  2015-01-06       Impact factor: 5.640

10.  Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Authors:  A R Hanauske; G Catimel; S Aamdal; W ten Bokkel Huinink; R Paridaens; N Pavlidis; S B Kaye; A te Velde; J Wanders; J Verweij
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.